Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005


HIV-1 Genetic Diversity in Antenatal Cohort, Canada

Bertine S. Akouamba*†, Janique Viel*, Hugues Charest‡, Natacha Merindol*†, Johanne Samson*, Normand Lapointe*†, Bluma G. Brenner§, Richard Lalonde¶, P. Richard Harrigan#, Marc Boucher*†, and Hugo Soudeyns*†Comments to Author 
Author affiliations: *Hôpital Sainte-Justine, Montreal, Quebec, Canada; †Université de Montréal, Montreal, Quebec, Canada; ‡Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada; §Lady Davis Institute for Medical Research, Montreal, Quebec, Canada; ¶McGill University Health Center, Montreal, Quebec, Canada; #British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada

Main Article


Viral and immune parameters in study participants*

Treatment naive
Median (IQR) viral load (log copies/mL)† % viral load <2.7 (n)‡ % viral load <1.7 (n)‡ Median (IQR) CD4+ count (cells/μL)† % receiving ARV therapy (n)‡ Median (IQR) viral load (log copies/mL)† Median (IQR) CD4+ cell count in treatment-naive patients (cells/μL)†
HIV-1 B clade 3.61 (1.71) 28.8 (17) 11.9 (7) 360 (285) 44.1 (26) 3.95 (1.38) 418 (278)
HIV-1 non-B clade 3.52 (1.39) 22.7 (10) 2.27 (1) 351 (220) 20.5 (9) 3.53 (0.94) 327 (208)
p value 0.927 0.508 0.316 0.476 0.0102§ 0.143 0.107

*HIV-1 viral load and CD4+ cell counts were measured as described in Patients and Methods. Significance of differences between groups was tested by Kruskal-Wallis test or Fisher exact test. Analysis was carried out on the whole study group (N = 103) or restricted to those who did not receive treatment (n = 61). IQR, interquartile range; ARV, antiretroviral.
†Kruskal-Wallis test.
‡Fisher exact test.
§Statistically significant (p<0.05) by directional test.

Main Article